-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
How Much Of Ascletis Pharma Inc. (HKG:1672) Do Insiders Own?
How Much Of Ascletis Pharma Inc. (HKG:1672) Do Insiders Own?
Every investor in Ascletis Pharma Inc. (HKG:1672) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
With a market capitalization of HK$4.0b, Ascletis Pharma is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions are not really that prevalent on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Ascletis Pharma.
See our latest analysis for Ascletis Pharma
SEHK:1672 Ownership Breakdown July 13th 2022What Does The Institutional Ownership Tell Us About Ascletis Pharma?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Since institutions own only a small portion of Ascletis Pharma, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. So if the company itself can improve over time, we may well see more institutional buyers in the future. It is not uncommon to see a big share price rise if multiple institutional investors are trying to buy into a stock at the same time. So check out the historic earnings trajectory, below, but keep in mind it's the future that counts most.
SEHK:1672 Earnings and Revenue Growth July 13th 2022We note that hedge funds don't have a meaningful investment in Ascletis Pharma. With a 51% stake, CEO Jinzi Jason Wu is the largest shareholder. This implies that they possess majority interests and have significant control over the company. Investors usually consider it a good sign when the company leadership has such a significant stake, as this is widely perceived to increase the chance that the management will act in the best interests of the company. In comparison, the second and third largest shareholders hold about 9.7% and 6.0% of the stock.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.
Insider Ownership Of Ascletis Pharma
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our most recent data indicates that insiders own the majority of Ascletis Pharma Inc.. This means they can collectively make decisions for the company. So they have a HK$2.6b stake in this HK$4.0b business. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 21% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
We can see that Private Companies own 12%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.
I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Ascletis Pharma Inc.(HKG:1672)的每一位投資者都應該知道最強大的股東羣體。內部人士通常持有大量較年輕、規模較小的公司,而大公司往往有機構作為股東。沃倫·巴菲特説,他喜歡“一家由有能力、以所有者為導向的人經營的、具有持久競爭優勢的企業”。因此,看到一些內部人持股是件好事,因為這可能表明管理層是以所有者為導向的。
Ascletis Pharma的市值為40億港元,是一隻小盤股,因此可能並不為許多機構投資者所熟知。在下面的圖表中,我們可以看到,機構在股票登記處並不是真的那麼普遍。讓我們仔細看看不同類型的股東能告訴我們關於Ascletis Pharma的什麼。
查看我們對Ascletis Pharma的最新分析
聯交所:1672所有權分類2022年7月13日關於Ascletis Pharma,機構所有權告訴了我們什麼?
機構投資者通常將自己的回報與經常跟蹤的指數的回報進行比較。因此,他們通常確實會考慮收購被納入相關基準指數的較大公司。
由於機構只擁有Ascletis Pharma的一小部分股份,許多機構可能沒有花太多時間考慮這隻股票。但很明顯,有些人已經這樣做了;他們非常喜歡它,於是就買入了。因此,如果公司本身能夠隨着時間的推移而改善,我們很可能會在未來看到更多的機構買家。如果多個機構投資者試圖同時買入一隻股票,股價大幅上漲的情況並不少見。所以,看看下面的歷史收益軌跡,但要記住,未來才是最重要的。
聯交所:1672盈利及收入增長2022年7月13日我們注意到,對衝基金沒有對Ascletis Pharma進行有意義的投資。持有51%股份的金姿CEO吳季剛是最大股東。這意味着他們擁有多數股權,並對公司擁有重大控制權。投資者通常認為,當公司領導層持有如此多的股份時,這是一個好兆頭,因為人們普遍認為,這增加了管理層採取行動符合公司最佳利益的可能性。相比之下,第二大和第三大股東分別持有約9.7%和6.0%的股份。
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒,也可以達到同樣的效果。分析師對該股的報道不多,但也不多。因此,它有獲得更多報道的空間。
Ascletis Pharma的內部人所有權
不同國家對內部人的定義可能略有不同,但董事會成員總是算數的。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。
我通常認為內部人持股是一件好事。然而,在某些情況下,這會讓其他股東更難讓董事會對決策負責。
我們最新的數據顯示,內部人士擁有Ascletis Pharma Inc.的大部分股份。這意味着他們可以集體為公司做出決定。因此,他們在這項價值40億港元的業務中持有26億港元的股份。大多數人會辯稱,這是積極的,表明了與股東的強烈一致。你可以點擊這裏,看看這些內部人士是一直在買入還是賣出。
一般公有制
包括散户投資者在內的普通公眾持有該公司21%的股份,因此不能輕易忽視。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
私營公司所有權
我們可以看到,私營公司擁有12%的已發行股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
我發現看看到底是誰擁有一家公司是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他信息。
我喜歡潛入更深的地方瞭解一家公司過去的表現。您可以訪問此互動圖過去的收益、收入和現金流,是免費的。
如果你更願意瞭解分析師對未來增長的預測,請不要錯過這一預期免費關於分析師預測的報告。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧